Lamon K D
Rorer Central Reseach, Horsham, PA 19044.
Am Heart J. 1988 Nov;116(5 Pt 2):1438-40. doi: 10.1016/0002-8703(88)90138-x.
Celiprolol hydrochloride is a highly cardioselective beta1-adrenergic antagonist with a unique pharmacologic profile. The adverse experience safety data derived from 18 double-blind trials (n = 2884) were evaluated. The results demonstrated a wide margin of safety for celiprolol over the recommended dosage range of 200 to 600 mg once daily. Celiprolol exhibited an adverse experience profile similar to that of placebo and resulted in a lower incidence of bradycardia and age-associated increases in adverse event rates compared with atenolol and propranolol.
盐酸塞利洛尔是一种具有独特药理特性的高度心脏选择性β1肾上腺素能拮抗剂。对来自18项双盲试验（n = 2884）的不良事件安全性数据进行了评估。结果表明，在每日一次200至600毫克的推荐剂量范围内，塞利洛尔具有广泛的安全边际。塞利洛尔的不良事件谱与安慰剂相似，与阿替洛尔和普萘洛尔相比，心动过缓的发生率较低，且不良事件发生率随年龄增长的增幅较小。
